Epi-drugs and epi-mirs: Moving beyond current cancer therapies

Reza Salarinia; Amirhossein Sahebkar; Mostafa Peyvandi; Hamid Reza Mirzaei; Mahmoud Reza Jaafari; Maryam Matbou Riahi; Hamed Ebrahimnejad; Javid Sadri Nahand; Jamshid Hadjati; Mobina Ostadi Asrami; Sara Fadaei; Rasoul Salehi; Hamed Mirzaei

doi:10.2174/1568009616666151207110143

Epi-drugs and epi-mirs: Moving beyond current cancer therapies

Reza Salarinia
, Amirhossein Sahebkar
, Mostafa Peyvandi
, Hamid Reza Mirzaei
, Mahmoud Reza Jaafari
, Maryam Matbou Riahi
, Hamed Ebrahimnejad
, Javid Sadri Nahand
, Jamshid Hadjati
, Mobina Ostadi Asrami
, Sara Fadaei
, Rasoul Salehi
, Hamed Mirzaei

Research output: Contribution to journal › Review article › peer-review

120 Scopus citations

Abstract

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.

Original language	English (US)
Pages (from-to)	773-788
Number of pages	16
Journal	Current cancer drug targets
Volume	16
Issue number	9
DOIs	https://doi.org/10.2174/1568009616666151207110143
State	Published - Nov 1 2016
Externally published	Yes

Keywords

Cancer epigenetics
DNA methyltransferase inhibitor
Epi-drugs
Epi-miRs
Histone deacetylase inhibitor

ASJC Scopus subject areas

Oncology
Pharmacology
Drug Discovery
Cancer Research

Access to Document

10.2174/1568009616666151207110143

Cite this

@article{ddafde6aef0f4aa4bcd9f02be287d9d8,

title = "Epi-drugs and epi-mirs: Moving beyond current cancer therapies",

abstract = "Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.",

keywords = "Cancer epigenetics, DNA methyltransferase inhibitor, Epi-drugs, Epi-miRs, Histone deacetylase inhibitor",

author = "Reza Salarinia and Amirhossein Sahebkar and Mostafa Peyvandi and Mirzaei, \{Hamid Reza\} and Jaafari, \{Mahmoud Reza\} and Riahi, \{Maryam Matbou\} and Hamed Ebrahimnejad and Nahand, \{Javid Sadri\} and Jamshid Hadjati and Asrami, \{Mobina Ostadi\} and Sara Fadaei and Rasoul Salehi and Hamed Mirzaei",

note = "Publisher Copyright: {\textcopyright} 2016 Bentham Science Publishers.",

year = "2016",

month = nov,

day = "1",

doi = "10.2174/1568009616666151207110143",

language = "English (US)",

volume = "16",

pages = "773--788",

journal = "Current cancer drug targets",

issn = "1568-0096",

publisher = "Bentham Science Publishers",

number = "9",

}

TY - JOUR

T1 - Epi-drugs and epi-mirs

T2 - Moving beyond current cancer therapies

AU - Salarinia, Reza

AU - Sahebkar, Amirhossein

AU - Peyvandi, Mostafa

AU - Mirzaei, Hamid Reza

AU - Jaafari, Mahmoud Reza

AU - Riahi, Maryam Matbou

AU - Ebrahimnejad, Hamed

AU - Nahand, Javid Sadri

AU - Hadjati, Jamshid

AU - Asrami, Mobina Ostadi

AU - Fadaei, Sara

AU - Salehi, Rasoul

AU - Mirzaei, Hamed

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.

AB - Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.

KW - Cancer epigenetics

KW - DNA methyltransferase inhibitor

KW - Epi-drugs

KW - Epi-miRs

KW - Histone deacetylase inhibitor

UR - https://www.scopus.com/pages/publications/84995543375

UR - https://www.scopus.com/pages/publications/84995543375#tab=citedBy

U2 - 10.2174/1568009616666151207110143

DO - 10.2174/1568009616666151207110143

M3 - Review article

C2 - 26638884

AN - SCOPUS:84995543375

SN - 1568-0096

VL - 16

SP - 773

EP - 788

JO - Current cancer drug targets

JF - Current cancer drug targets

IS - 9

ER -

Epi-drugs and epi-mirs: Moving beyond current cancer therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this